Packaged Foods
Build Your Comparison
Side-by-side financial analysisStock Comparison
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
REIT - Residential
REIT - Residential
Medical - Healthcare Information Services
Banks - Diversified
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Packaged Foods | Medical - Equipment & Services | REIT - Residential | REIT - Residential | Medical - Healthcare Information Services | Banks - Diversified |
| Market Cap | $144K | $6.62B | $696M | $3.91B | $1.35B | $892.31B |
| Revenue (TTM) | $19M | $2.37B | $252M | $662M | $2.51B | $280.33B |
| Net Income (TTM) | $-15M | $-13M | $-32M | $48M | $-171M | $57.05B |
| Gross Margin | 10.5% | 67.6% | 91.1% | 20.2% | 65.6% | 60.0% |
| Operating Margin | -60.4% | 1.3% | 11.5% | 17.5% | -7.6% | 25.9% |
| Forward P/E | — | 59.2x | — | 113.5x | — | 14.3x |
| Total Debt | $24M | $1.26B | $1.56B | $2.28B | $1.04B | $942.38B |
| Cash & Equiv. | $369K | $229M | $14M | $48M | $781M | $343.34B |
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Stryve Foods, Inc. (SNAX) | 100 | 0.0 | -100.0% |
| Hims & Hers Health,… (HIMS) | 100 | 257.1 | +157.1% |
| NexPoint Residentia… (NXRT) | 100 | 82.2 | -17.8% |
| Independence Realty… (IRT) | 100 | 141.3 | +41.3% |
| Teladoc Health, Inc. (TDOC) | 100 | 4.0 | -96.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 318.2 | +218.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 6 stocks, SNAX doesn't own a clear edge in any measured category.
HIMS is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs SNAX's -40.9%
NXRT ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 11 yrs, beta 0.53, yield 7.7%
- Beta 0.53, yield 7.7%, current ratio 0.48x
- 7.7% yield, 11-year raise streak, vs JPM's 1.9%, (3 stocks pay no dividend)
IRT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.30, Low D/E 63.6%, current ratio 0.05x
- Beta 0.30 vs HIMS's 2.48, lower leverage
TDOC doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
JPM carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 475.6% 10Y total return vs HIMS's 207.9%
- Lower P/E (14.3x vs 113.5x)
- 20.4% margin vs SNAX's -79.1%
- +20.3% vs SNAX's -87.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs SNAX's -40.9% | |
| Value | Lower P/E (14.3x vs 113.5x) | |
| Quality / Margins | 20.4% margin vs SNAX's -79.1% | |
| Stability / Safety | Beta 0.30 vs HIMS's 2.48, lower leverage | |
| Dividends | 7.7% yield, 11-year raise streak, vs JPM's 1.9%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +20.3% vs SNAX's -87.3% | |
| Efficiency (ROA) | 1.3% ROA vs SNAX's -47.8%, ROIC 4.5% vs -39.0% |
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 1 of 6 categories
IRT leads 1 • HIMS leads 1 • SNAX leads 0 • NXRT leads 0 • TDOC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 14477.0x SNAX's $19M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to SNAX's -79.1%. On growth, SNAX holds the edge at +36.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $19M | $2.4B | $252M | $662M | $2.5B | $280.3B |
| EBITDAEarnings before interest/tax | -$9M | $99M | $125M | $365M | $42M | $81.4B |
| Net IncomeAfter-tax profit | -$15M | -$13M | -$32M | $48M | -$171M | $57.0B |
| Free Cash FlowCash after capex | -$6M | $76M | $79M | $139M | $251M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +10.5% | +67.6% | +91.1% | +20.2% | +65.6% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -60.4% | +1.3% | +11.5% | +17.5% | -7.6% | +25.9% |
| Net MarginNet income ÷ Revenue | -79.1% | -0.6% | -12.7% | +7.3% | -6.8% | +20.4% |
| FCF MarginFCF ÷ Revenue | -32.2% | +3.2% | +31.2% | +21.1% | +10.0% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.4% | +3.8% | +0.5% | +2.5% | -2.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | -3.0% | 0.0% | -101.4% | +32.1% | +16.0% |
Valuation Metrics
Evenly matched — SNAX and TDOC each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 15.9x trailing earnings, JPM trades at a 77% valuation discount to IRT's 69.1x P/E. On an enterprise value basis, TDOC's 16.0x EV/EBITDA is more attractive than HIMS's 47.8x.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $143,748 | $6.6B | $696M | $3.9B | $1.3B | $892.3B |
| Enterprise ValueMkt cap + debt − cash | $24M | $7.7B | $2.2B | $6.1B | $1.6B | $1.49T |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | 59.16x | -21.76x | 69.13x | -6.54x | 15.93x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 113.47x | — | 14.34x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | 47.84x | 18.11x | 16.86x | 16.02x | 18.32x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 2.82x | 2.77x | 5.94x | 0.53x | 3.19x |
| Price / BookPrice ÷ Book value/share | 0.05x | 14.40x | 2.32x | 1.08x | 0.95x | 2.46x |
| Price / FCFMarket cap ÷ FCF | — | 89.56x | 8.32x | 26.68x | 4.72x | 8.85x |
Profitability & Efficiency
IRT leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-2 for SNAX. IRT carries lower financial leverage with a 0.64x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNAX's 15.06x. On the Piotroski fundamental quality scale (0–9), IRT scores 6/9 vs SNAX's 3/9, reflecting solid financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -2.5% | -10.1% | +1.3% | -12.4% | +15.9% |
| ROA (TTM)Return on assets | -47.8% | -0.6% | -1.7% | +0.8% | -5.9% | +1.3% |
| ROICReturn on invested capital | -39.0% | +8.6% | +1.1% | +1.6% | -11.5% | +4.5% |
| ROCEReturn on capital employed | -62.4% | +9.4% | +1.5% | +2.4% | -10.0% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 4 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 15.06x | 2.34x | 5.18x | 0.64x | 0.75x | 2.60x |
| Net DebtTotal debt minus cash | $24M | $1.0B | $1.5B | $2.2B | $259M | $599.0B |
| Cash & Equiv.Liquid assets | $369,114 | $229M | $14M | $48M | $781M | $343.3B |
| Total DebtShort + long-term debt | $24M | $1.3B | $1.6B | $2.3B | $1.0B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -3.69x | — | 0.47x | 1.73x | -8.76x | 0.74x |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $24,996 today (with dividends reinvested), compared to $2 for SNAX. Over the past 12 months, JPM leads with a +20.3% total return vs SNAX's -87.3%. The 3-year compound annual growth rate (CAGR) favors HIMS at 50.8% vs SNAX's -85.1% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1000.0% | -9.7% | -3.7% | -4.8% | +5.8% | -0.9% |
| 1-Year ReturnPast 12 months | -87.3% | -49.5% | -9.7% | -3.9% | +6.3% | +20.3% |
| 3-Year ReturnCumulative with dividends | -99.7% | +242.8% | -27.4% | -0.4% | -70.4% | +133.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | +150.0% | -35.4% | +6.1% | -95.1% | +120.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | +207.9% | +170.0% | +202.4% | -42.8% | +475.6% |
| CAGR (3Y)Annualised 3-year return | -85.1% | +50.8% | -10.1% | -0.1% | -33.4% | +32.7% |
Risk & Volatility
Evenly matched — SNAX and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
SNAX is the less volatile stock with a -3.16 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 94.7% from its 52-week high vs SNAX's 8.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -3.16x | 2.48x | 0.53x | 0.30x | 1.85x | 0.94x |
| 52-Week HighHighest price in past year | $0.39 | $70.43 | $35.08 | $18.27 | $9.77 | $337.25 |
| 52-Week LowLowest price in past year | $0.00 | $13.74 | $23.79 | $14.60 | $4.40 | $266.85 |
| % of 52W HighCurrent price vs 52-week peak | +8.5% | +42.8% | +78.2% | +90.8% | +76.4% | +94.7% |
| RSI (14)Momentum oscillator 0–100 | 66.4 | 51.5 | 50.1 | 59.6 | 59.0 | 65.0 |
| Avg Volume (50D)Average daily shares traded | 584 | 24.7M | 160K | 2.2M | 4.4M | 7.0M |
Analyst Outlook
Evenly matched — NXRT and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: HIMS as "Hold", NXRT as "Hold", IRT as "Buy", TDOC as "Hold", JPM as "Buy". Consensus price targets imply 17.5% upside for IRT (target: $20) vs -10.5% for HIMS (target: $27). For income investors, NXRT offers the higher dividend yield at 7.69% vs JPM's 1.86%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $27.00 | $27.00 | $19.50 | $7.40 | $339.75 |
| # AnalystsCovering analysts | — | 20 | 10 | 27 | 42 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +7.7% | +4.0% | — | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | — | 11 | 4 | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $2.11 | $0.66 | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | +1.1% | +0.8% | 0.0% | +3.9% |
JPM leads in 1 of 6 categories (Income & Cash Flow). IRT leads in 1 (Profitability & Efficiency). 3 tied.
SNAX vs HIMS vs NXRT vs IRT vs TDOC vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNAX or HIMS or NXRT or IRT or TDOC or JPM a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -40. 9% for Stryve Foods, Inc. (SNAX). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Independence Realty Trust, Inc. (IRT) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 15. 9x versus Independence Realty Trust, Inc. at 69. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 3x.
03Which is the better long-term investment — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +150. 0%, compared to -100. 0% for Stryve Foods, Inc. (SNAX). Over 10 years, the gap is even starker: JPM returned +475. 6% versus SNAX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
By beta (market sensitivity over 5 years), Stryve Foods, Inc.
(SNAX) is the lower-risk stock at -3. 16β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately -179% more volatile than SNAX relative to the S&P 500. On balance sheet safety, Independence Realty Trust, Inc. (IRT) carries a lower debt/equity ratio of 64% versus 15% for Stryve Foods, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -40. 9% for Stryve Foods, Inc. (SNAX). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -30. 8% for NexPoint Residential Trust, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -107. 5% for Stryve Foods, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -87. 1% for SNAX. At the gross margin level — before operating expenses — NXRT leads at 84. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNAX or HIMS or NXRT or IRT or TDOC or JPM more undervalued right now?
On forward earnings alone, JPMorgan Chase & Co.
(JPM) trades at 14. 3x forward P/E versus 113. 5x for Independence Realty Trust, Inc. — 99. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IRT: 17. 5% to $19. 50.
08Which pays a better dividend — SNAX or HIMS or NXRT or IRT or TDOC or JPM?
In this comparison, NXRT (7.
7% yield), IRT (4. 0% yield), JPM (1. 9% yield) pay a dividend. SNAX, HIMS, TDOC do not pay a meaningful dividend and should not be held primarily for income.
09Is SNAX or HIMS or NXRT or IRT or TDOC or JPM better for a retirement portfolio?
For long-horizon retirement investors, Stryve Foods, Inc.
(SNAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -3. 16)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SNAX: -100. 0%, TDOC: -42. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNAX and HIMS and NXRT and IRT and TDOC and JPM?
These companies operate in different sectors (SNAX (Consumer Defensive) and HIMS (Healthcare) and NXRT (Real Estate) and IRT (Real Estate) and TDOC (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SNAX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; NXRT is a small-cap income-oriented stock; IRT is a small-cap income-oriented stock; TDOC is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. NXRT, IRT, JPM pay a dividend while SNAX, HIMS, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.